NasdaqGS - Nasdaq Real Time Price USD
Syros Pharmaceuticals, Inc. (SYRS)
As of 11:18 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,149.0000
9,936.0000
14,880.0000
23,488.0000
15,093.0000
Operating Expense
121,773.0000
136,435.0000
141,243.0000
122,908.0000
97,390.0000
Operating Income
-117,624.0000
-126,499.0000
-126,363.0000
-99,420.0000
-82,297.0000
Net Non Operating Interest Income Expense
226.0000
1,689.0000
-2,002.0000
-3,820.0000
-1,366.0000
Other Income Expense
-14,164.0000
-39,764.0000
33,711.0000
16,682.0000
-375.0000
Pretax Income
-131,562.0000
-164,574.0000
-94,654.0000
-86,558.0000
-84,038.0000
Net Income Common Stockholders
-131,562.0000
-164,574.0000
-94,654.0000
-86,558.0000
-84,038.0000
Diluted NI Available to Com Stockholders
-131,562.0000
-164,574.0000
-94,654.0000
-86,558.0000
-84,038.0000
Basic EPS
-4.35
-5.81
-7.49
-13.84
-18.20
Diluted EPS
-4.35
-5.81
-7.49
-13.84
-18.20
Basic Average Shares
33,948.6340
28,325.7790
12,631.9680
6,253.4980
4,605.1620
Diluted Average Shares
33,948.6340
28,325.7790
12,631.9680
6,253.4980
4,605.1620
Total Operating Income as Reported
-120,113.0000
-128,988.0000
-135,873.0000
-99,420.0000
-82,297.0000
Total Expenses
121,773.0000
136,435.0000
141,243.0000
122,908.0000
97,390.0000
Net Income from Continuing & Discontinued Operation
-131,562.0000
-164,574.0000
-94,654.0000
-86,558.0000
-84,038.0000
Normalized Income
-117,398.0000
-124,810.0000
-128,365.0000
-103,240.0000
-83,663.0000
Interest Income
5,547.0000
6,816.0000
2,132.0000
87.0000
426.0000
Interest Expense
5,321.0000
5,127.0000
4,134.0000
3,907.0000
1,792.0000
Net Interest Income
226.0000
1,689.0000
-2,002.0000
-3,820.0000
-1,366.0000
EBIT
-126,241.0000
-159,447.0000
-90,520.0000
-82,651.0000
-82,246.0000
EBITDA
-124,612.0000
-157,195.0000
-87,814.0000
-79,633.0000
-79,211.0000
Reconciled Depreciation
1,629.0000
2,252.0000
2,706.0000
3,018.0000
3,035.0000
Net Income from Continuing Operation Net Minority Interest
-131,562.0000
-164,574.0000
-94,654.0000
-86,558.0000
-84,038.0000
Total Unusual Items Excluding Goodwill
-14,164.0000
-39,764.0000
33,711.0000
16,682.0000
-375.0000
Total Unusual Items
-14,164.0000
-39,764.0000
33,711.0000
16,682.0000
-375.0000
Normalized EBITDA
-110,448.0000
-117,431.0000
-121,525.0000
-96,315.0000
-78,836.0000
12/31/2020 - 6/30/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
EQ Equillium, Inc.
0.7900
-8.26%
LIXT Lixte Biotechnology Holdings, Inc.
2.0800
-1.42%
AVTE Aerovate Therapeutics, Inc.
2.7600
+12.65%
LXRX Lexicon Pharmaceuticals, Inc.
1.2991
-33.38%
LXEO Lexeo Therapeutics, Inc.
7.98
+1.01%
AMLX Amylyx Pharmaceuticals, Inc.
5.71
+5.76%
ATRA Atara Biotherapeutics, Inc.
9.30
+4.38%
KPTI Karyopharm Therapeutics Inc.
0.9772
-1.27%
TARS Tarsus Pharmaceuticals, Inc.
46.82
+5.24%
MCRB Seres Therapeutics, Inc.
0.8034
-2.00%